Principles and mechanisms of non-genetic resistance in cancer

被引:102
|
作者
Bell, Charles C. [1 ,2 ]
Gilan, Omer [1 ,2 ]
机构
[1] Peter MacCallum Canc Centre, Canc Res Div, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
BET BROMODOMAIN INHIBITORS; DRUG-RESISTANCE; GENE-EXPRESSION; ACQUIRED-RESISTANCE; CELL VARIABILITY; MEK INHIBITION; SINGLE CELLS; STEM-CELLS; HETEROGENEITY; EVOLUTION;
D O I
10.1038/s41416-019-0648-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As well as undergoing genetic evolution, cancer cells can alter their epigenetic state to adapt and resist treatment. This non-genetic evolution is emerging as a major component of cancer resistance. Only now are we beginning to acquire the necessary data and tools to establish some of the underlying principles and mechanisms that define when, why and how non-genetic resistance occurs. Preliminary studies suggest that it can exist in a number of forms, including drug persistence, unstable non-genetic resistance and, most intriguingly, stable non-genetic resistance. Exactly how they each arise remains unclear; however, epigenetic heterogeneity and plasticity appear to be important variables. In this review, we provide an overview of these different forms of non-genetic resistance, before exploring how epigenetic heterogeneity and plasticity influence their emergence. We highlight the distinction between non-genetic Darwinian selection and Lamarckian induction and discuss how each is capable of generating resistance. Finally, we discuss the potential interaction between genetic and non-genetic adaptation and propose the idea of 'the path of most resistance', which outlines the variables that dictate whether cancers adapt through genetic and/or epigenetic means. Through these discussions, we hope to provide a conceptual framework that focuses future studies, whose insights might help prevent or overcome non-genetic resistance.
引用
收藏
页码:465 / 472
页数:8
相关论文
共 50 条
  • [1] Principles and mechanisms of non-genetic resistance in cancer
    Charles C. Bell
    Omer Gilan
    British Journal of Cancer, 2020, 122 : 465 - 472
  • [2] Non-genetic mechanisms of therapeutic resistance in cancer
    Jean-Christophe Marine
    Sarah-Jane Dawson
    Mark A. Dawson
    Nature Reviews Cancer, 2020, 20 : 743 - 756
  • [3] Non-genetic mechanisms of therapeutic resistance in cancer
    Marine, Jean-Christophe
    Dawson, Sarah-Jane
    Dawson, Mark A.
    NATURE REVIEWS CANCER, 2020, 20 (12) : 743 - 756
  • [4] Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution
    Shlyakhtina, Yelyzaveta
    Moran, Katherine L.
    Portal, Maximiliano M.
    CANCERS, 2021, 13 (06) : 1 - 42
  • [5] The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer
    Salgia, Ravi
    Kulkarni, Prakash
    TRENDS IN CANCER, 2018, 4 (02): : 110 - 118
  • [6] Non-genetic mechanisms of drug resistance in acute leukemias
    Calderon, Alexander
    Han, Cuijuan
    Karma, Sadik
    Wang, Eric
    TRENDS IN CANCER, 2024, 10 (01) : 38 - 51
  • [7] A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer
    Kulkarni, Prakash
    Mohanty, Atish
    Ramisetty, Sravani
    Duvivier, Herbert
    Khan, Ajaz
    Shrestha, Sagun
    Tan, Tingting
    Merla, Amartej
    El-Hajjaoui, Michelle
    Malhotra, Jyoti
    Singhal, Sharad
    Salgia, Ravi
    BIOMOLECULES, 2023, 13 (11)
  • [8] Editorial: Non-genetic adaptive drug resistance in cancer
    Cerezo, Michael
    Sun, Xiaoxiao
    Shen, Shensi
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [9] Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy
    Symeonidou, Vasiliki
    Metzner, Marlen
    Usukhbayar, Batchimeg
    Jackson, Aimee E.
    Fox, Sonia
    Craddock, Charles F.
    Vyas, Paresh
    EJHAEM, 2022, 3 (03): : 794 - 803
  • [10] Hsp90 Inhibitors and the Reduction of Anti-Cancer Drug Resistance by Non-Genetic and Genetic Mechanisms
    Lu, Xiangyi
    Wang, Luan
    Ruden, Douglas M.
    PHARMACEUTICALS, 2012, 5 (09): : 890 - 898